Twice-daily subcutaneous injection of kisspeptin-54 does not abolish menstrual cyclicity in healthy female volunteers

What Was Tested

This controlled clinical trial paper looks at Kisspeptin-10 and Kisspeptin-54.

Their aim was to determine the effects of follicular-phase kisspeptin-54 treatment on menstrual cyclicity in healthy women.

Why It Was Studied

Kisspeptin is a critical hypothalamic regulator of reproductive function.

Chronic kisspeptin administration causes profound tachyphylaxis in male monkeys and in women with functional hypothalamic amenorrhea.

Who Took Part

By PubMed's age tags, the people studied were young adults and adults, women only.

Serial assessments of basal reproductive hormones, ultrasound parameters, LH pulsatility, and acute sensitivity to GnRH and kisspeptin-54 injection were performed.

How the Study Was Run

In design terms this was a single-blind, placebo-controlled and crossover study.

In this single-blind Kisspeptin-10 study one party knew the assignments and the other did not.

A placebo (an inactive look-alike) gave the Kisspeptin-10 group a baseline to be compared against.

In the crossover set-up each of the participants took both Kisspeptin-10 and the comparison in turn, acting as their own control.

The researchers performed a prospective, single-blinded, 1-way crossover study.

What Was Measured

The subject headings attached to it are Anovulation, Endometrium, Follicular Phase, Healthy Volunteers, Hormones, Kisspeptins and Luteal Phase.

What This Means in Plain Language

The paper is a single-blind, placebo-controlled and crossover study of Kisspeptin-10 and Kisspeptin-54.

Its findings take up roughly 5 sentences of the abstract and are left out here on purpose; the source paper is the place to read them.

The publication is from 2013 (The Journal of clinical endocrinology and metabolism), a journal based in United States.

More context: the Kisspeptin-10 compound page and the Kisspeptin-54 compound page, all human trials.